Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Clin Rheumatol. 2020 Nov;39(11):3527. doi: 10.1007/s10067-020-05410-y.

Abstract

This article originally published with the family name and given names of all authors transposed.

Publication types

  • Published Erratum